At a glance
ClinicalIndex Comparison Record- ✓Female patients with histologically or cytologically proven metastatic breast cancer (stage IV, or recurrent with local/regional spread or distant metastatic disease)
- ✕Adjuvant chemotherapy within the past 12 months
- ✕Uncontrolled brain metastases
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Placebo-Controlled, Double-Blind, Phase 2 Study Of AG-013736 In Combination With Docetaxel Versus Docetaxel Alone In Patients With Metastatic Breast Cancer Preceded By A Phase 1 Evaluation Of The Combination
In Brief
A Phase 2 clinical trial evaluating Placebo, Docetaxel, and 1 other intervention for Breast Neoplasms. Completed, enrolled 174 participants across 54 sites in 8 countries.
Detailed Summary
The primary purpose of the study is to determine the time to progression of the combination of study drug (AG-013736) and docetaxel versus docetaxel alone in patients who have not received prior chemotherapy for metastatic breast cancer. The secondary purpose of the study is to determine the dose of study drug that can be given with docetaxel administered on an every 3 week schedule.
Study Details
Timeline
Interventions
5 mg twice daily \[bid\] continuous dosing
Standard of care drug administration
5mg twice daily \[bid\] continuous dosing
Standard of care drug administration